旨在检查光生物调节疗法 (PBMT) 对癌症患者急性放射性皮炎 (ARD) 的有效性。检索了 PubMed、Embase、Cochrane Library 和 CINAHL 数据库建立至 2024 年 7 月之间发表的文章。随机对照试验 (RCT) 和研究 PBMT 对癌症患者 ARD 效果的非随机对照试验也纳入分析。使用随机效应模型进行荟萃分析和敏感性分析。针对癌症类型和 PBMT 目标（预防或治疗 ARD）进行亚组分析，并对不同级别的 ARD 进行分层。本荟萃分析中纳入了八项研究（五项随机对照试验和三项非随机对照试验）。与对照组相比，PBMT组2级和3级ARD发生率显着降低（风险差=-0.36，95%置信区间=-0.53至-0.19，I2=85%，P = < 0.00001）。亚组分析显示，与对照组相比，PBMT 对乳腺癌和头颈癌均具有显着效果。此外，PBMT 显着降低了 PBMT 组中预防和治疗亚组的 2 级和 3 级 ARD 发生率。PBMT 可能对乳腺癌和头颈癌患者的更高级别 ARD 的预防和治疗具有有益作用。然而，本荟萃分析中包含的研究表现出高度异质性。因此，必须谨慎解释结果。版权所有 © 2024。由 Elsevier B.V. 出版。

To examine the effectiveness of photobiomodulation therapy (PBMT) for acute radiation dermatitis (ARD) in patients with cancer.PubMed, Embase, Cochrane Library, and CINAHL were searched for articles published between database inception until July 2024. Randomized controlled trials (RCTs) and non-RCTs examining the effects of PBMT against ARD in patients with cancer were included for analysis. A random-effects model was used to conduct meta-analyses and sensitivity analyses. Subgroup analyses were conducted for cancer types and PBMT goals (prevention or treatment of ARD) with stratification for different grades of ARD.Eight studies (five RCTs and three non-RCTs) were included in this meta-analysis. Compared with the control group, the PBMT group exhibited significantly lower ARD incidence at grades 2 and 3 (risk difference =  - 0.36, 95 % confidence interval =  - 0.53 to - 0.19, I2 = 85 %, P = < 0.00001). Subgroup analyses revealed that, compared with the control group, PBMT had a significant effect on both breast cancer and head and neck cancer. In addition, PBMT significantly reduced grades 2 and 3 ARD incidence in the PBMT group for both prevention and treatment subgroups.PBMT may have beneficial effects on the prevention and treatment of higher-grade ARD in patients with breast cancer and head and neck cancer. Nevertheless, the studies included in this meta-analysis exhibited high heterogeneity. Therefore, the results must be interpreted with caution.Copyright © 2024. Published by Elsevier B.V.